Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Axovant Gene Therapies Dropped as Much as 16.6% Today

By Maxx Chatsko - Updated Apr 13, 2019 at 11:22AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma is wisely taking advantage of its lofty stock price to raise capital through a share offering.

What happened

Shares of Axovant Gene Therapies (AXGT -5.32%) fell more than 16% today after the company announced the pricing of a stock offering. The gene therapy developer will sell up to 30.7 million shares of common stock at $1.50 apiece, which could raise gross proceeds of up to $46 million. If the offering is completed in full, then the company's outstanding share count would increase by about 20%.

While the dilution will sting shareholders, issuing stock to raise money is a common feature of early-stage biopharma companies that need incredible amounts of capital to develop a drug pipeline. The proceeds from the offering will pad a balance sheet that entered 2019 with $84.9 million in cash and cash equivalents.

As of 10:45 a.m. EDT, the stock had settled to a 14.3% loss.

A graph drawn on a chalkboard showing a steady rise and then a sudden fall.

Image source: Getty Images.

So what

Dilution aside, the share offering is a wise move by management. Axovant Gene Therapies stock had gained 75% since the beginning of 2019 thanks to investor enthusiasm for any and all things related to gene therapies and early updates from two clinical programs that excited Wall Street earlier this week.

But the reality is that the company's pipeline is still years away from commercializing any of its drug candidates -- if it even harbors a successful product. Additionally, the recent update from the clinic included partial data from just three patients. Therefore, it was a little too early for individual investors or analysts to get that excited, but taking advantage of a lofty stock price to raise capital is a smart thing to do.

Check out the latest earnings call transcripts for the companies we cover.

Now what

There's not much shareholders can do about the stock offering. It's a common way for companies that have few other sources of income to raise capital. Axovant Gene Therapies will likely use it again, judging by the early-stage nature of its pipeline. And the company's shares will likely be volatile throughout 2019 so long as gene therapies are an attractive investment theme.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Axovant Gene Therapies Ltd. Stock Quote
Axovant Gene Therapies Ltd.
AXGT
$0.27 (-5.32%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.